Verona Pharma has appointed Dr. Martin Edwards to the board as a non-executive director.
Dr. Edwards has over three decades of experience in the pharmaceutical and venture capital industries and is currently senior partner of Novo Holdings, where he has held various positions since 2003.
Dr. Edwards is also chairman of the Board of Directors of Vantia Therapeutics Ltd and a member of the Board of Directors of F2G, Harmony Biosciences, Inozyme Pharma, Karus Therapeutics, Nuvelution Pharma and Tarsa Therapeutics.
Commenting on the appointment, Dr. David Ebsworth, chairman of Verona, said: “We are delighted to welcome Martin to our Board. His substantial expertise in the sector, along with his unique leadership insights and perspective, will be valuable as we continue to advance ensifentrine into late-stage clinical development.”
Dr. Edwards trained in physiology and medicine at the University of Manchester, and is a Member of the Royal College of Physicians.
